Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2004;44:300-304
Published online before print July 12, 2004, doi: 10.1161/01.HYP.0000137380.91476.fb
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
44/3/300    most recent
01.HYP.0000137380.91476.fbv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hrafnkelsdóttir, T.
Right arrow Articles by Jern, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hrafnkelsdóttir, T.
Right arrow Articles by Jern, S.
Related Collections
Right arrow Other hypertension
Right arrow Fibrinolysis
Right arrow Arterial thrombosis
Right arrow Endothelium/vascular type/nitric oxide

(Hypertension. 2004;44:300.)
© 2004 American Heart Association, Inc.


Scientific Contributions

Impaired Endothelial Release of Tissue-Type Plasminogen Activator in Patients With Chronic Kidney Disease and Hypertension

Thórdís Hrafnkelsdóttir; Pia Ottosson; Thorarinn Gudnason; Ola Samuelsson; Sverker Jern

From the Clinical Experimental Research Laboratory (T.H., T.G., S.J.), Sahlgrenska University Hospital/Östra, and the Department of Nephrology (P.O., O.S.), Sahlgrenska University Hospital/Sahlgrenska, Göteborg University, Sweden.

Correspondence to Dr Thórdís Hrafnkelsdóttir, Clinical Experimental Research Laboratory, Sahlgrenska University Hospital/Östra, SE 41685 Göteborg, Sweden. E-mail thordis.hrafnkelsdottir{at}hjl.gu.se

We have shown that the capacity for local release of tissue-type plasminogen activator (tPA) from the vascular endothelium is impaired in patients with primary hypertension. Because this response is an important protective mechanism against intravascular clotting, we investigated whether this system is also defective in patients with advanced chronic kidney disease and hypertension. Nine nondiabetic nonsmoking men with chronic kidney disease (glomerular filtration rate 11 to 28 mL/minx1.73 m2; aged 33 to 75 years) were compared with age-matched healthy controls. Intraarterial infusions of desmopressin, methacholine, and sodium nitroprusside were given locally in the brachial artery. Forearm blood flow was measured by venous occlusion plethysmography and blood collected repeatedly during the desmopressin infusion for determination of stimulated net and total cumulated release of tPA. The maximal release rate of active tPA (P<0.05) and the capacity for acute tPA release were markedly impaired in the renal patients as compared with healthy subjects (ANOVA, P=0.013). Accordingly, the accumulated release of tPA was 1905 (SEM 366) and 3387 (718) ng/L tissue, respectively (P<0.05). However, there were no significant differences in vasodilator responses between the groups. Thus, patients with advanced chronic kidney disease and hypertension have a markedly impaired capacity for acute release of tissue plasminogen activator, despite preserved endothelium-dependent vasodilation. This defect may contribute to a defective local defense against arterial thrombosis.


Key Words: kidney failure • endothelium • hypertension, essential • tissue-type plasminogen activator • hypertension, renal




This article has been cited by other articles:


Home page
StrokeHome page
G. Tsivgoulis, M. Saqqur, V. K. Sharma, A. Y. Lao, M. D. Hill, A. V. Alexandrov, and for the CLOTBUST Investigators
Association of Pretreatment Blood Pressure With Tissue Plasminogen Activator-Induced Arterial Recanalization in Acute Ischemic Stroke
Stroke, March 1, 2007; 38(3): 961 - 966.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. G. Wannamethee, A. G. Shaper, G. D.O. Lowe, L. Lennon, A. Rumley, and P. H. Whincup
Renal function and cardiovascular mortality in elderly men: the role of inflammatory, procoagulant, and endothelial biomarkers
Eur. Heart J., December 2, 2006; 27(24): 2975 - 2981.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. Ridderstrale, E. Ulfhammer, S. Jern, and T. Hrafnkelsdottir
Impaired Capacity for Stimulated Fibrinolysis in Primary Hypertension Is Restored by Antihypertensive Therapy
Hypertension, April 1, 2006; 47(4): 686 - 691.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. J. Oliver, D. J. Webb, and D. E. Newby
Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans
Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2470 - 2479.
[Abstract] [Full Text] [PDF]